Investing in rapidly expanding biotech stocks can be a worthwhile long-term investment. Just one successful drug or device ...

CFTX-1554 is under clinical development by Eli Lilly and Co and currently in Phase I for Peripheral Neuropathic Pain.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Eli Lilly fair value estimate is US$1,319 Current share ...

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

The Huminsulin range is vital for managing both type 1 and type 2 diabetes, helping control blood sugar levels in adults and ...

Lupin strengthens its diabetes portfolio with the acquisition of Huminsulin products from Eli Lilly, including Insulin Human ...

Lupin Ltd acquires Huminsulin from Eli Lilly to expand diabetes portfolio, offering a range of human insulin options.

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE ... stock crashed by 19% on Dec. 20, after the company reported results from a late-stage clinical trial that it framed as a success.

Lupin has been marketing the 'Huminsulin' range of products through existing distribution and promotion agreements with Eli ...